Purpose of review Systemic medications may cause side-effects manifesting primarily as neuro-ophthalmologic problems. It is paramount for the physician to be updated on both well recognized and novel associations between drugs and their potential adverse reactions.
INTRODUCTION
Our modern healthcare system encourages physicians to frequently review and reconcile the patient medication list. Electronic medical records have made this task more manageable, but physicians are doubling their efforts to remain updated on medication side-effects and adverse reactions.
Ocular side-effects may occur due to prescription, homeopathic, or herbal medications [1] [2] [3] . Neither the prescribing physician nor the patient may be aware of these potential complications. Furthermore, the Food and Drug Administrationapproved product labeling information for many medications is broad and generic; 'blurry vision' is an ubiquitous side-effect that provides little guidance for the physician.
This article aims to provide an updated review of ocular side-effects of systemic medications specifically relevant in neuro-ophthalmology. Examples of visual side-effects other than those particular to neuro-ophthalmology are summarized in Table 1 [4, 5, 6 & -9 & , 10, 11] . Reported medication side-effects must be interpreted with perspective. For example, the ophthalmic effects of some medications are undeniable and obvious, such as atropine causing mydriasis. Others have very strong evidence and the pathophysiology is clear, such as worsening of myasthenic weakness after botulinum toxin injection. However, verification for some purported medication-side-effect relationships has not been made. For example, evidence is not conclusive that b-blockers worsen myasthenia gravis, or that phosphodiesterase type five (PDE-5) inhibitors cause ischemic optic neuropathy, despite conventional belief that these effects are proven. Furthermore, other medications have been associated with an adverse ophthalmologic event based only on one or several case descriptions. Some of these reports were released prior to MRI, and have not been reconfirmed, yet persist in tables and lists. Thus, for any medication-side-effect relationship, it is important to consider the strength of evidence and pathophysiological reasoning.
MEDICATIONS THAT MAY AFFECT THE PUPIL
Medications that increase pupil size could result in bilaterally symmetric pupil dilation or unilateral mydriasis. The latter situation may mimic an acute incipient compressive third nerve palsy and often prompts emergent evaluation. Unilateral mydriasis usually results from effects of medication directly contacting the ocular surface. This can occur from mydriatic drops whose primary function is to produce pupillary dilatation, or it can occur as an unintended side-effect of other medications. We have seen unilateral eye dilation in the intensive care setting due to aerosolized respiratory therapies containing ipratropium and albuterol asymmetrically escaping the facemask or ventilator equipment [12] . If it contacts the eye, transdermal scopolamine can also cause unilateral mydriasis due to its anticholinergic properties. Scopolamine has been reported to cause unilateral pupil dilation when used as an antiemetic in patients taking chemotherapy [13] and for prevention of postoperative nausea after plastic and reconstructive surgery [14 & ], highlighting the increased recognition of this side-effect.
Unilateral eye dilation should also prompt questioning for over-the-counter medication use. One report described a patient who was evaluated in the emergency department for acute unilateral mydriasis. She was found to be using a hemorrhoidal cream to decrease puffiness around her eyes. The cream contained phenylephrine 0.25% [15] .
Either prescription or illicit drugs can cause bilateral pupil dilation, and are listed in Table 2 . Bilateral pupil dilation is a classic sign of anticholinergic toxicity, which also produces confusion, flushing, dry skin, fever, tachycardia, bowel stasis, myoclonus, and urinary retention. Both prescription and herbal medicines can result in anticholinergic toxicity. Pupillary mydriasis is the most common clinical feature when anticholinergic poisoning is caused by Chinese herbal medicines [16 & ]. Conversely, some drugs have the potential to cause pupil constriction. Organophosphates, used as pesticides and nerve agents, are the prototypical miotic agents due to their cholinergic effects. Medications that cause miosis are not as likely to cause anisocoria, but may result in bilaterally miotic pupils (Table 3 [ 17] ).
MEDICATIONS THAT MAY CAUSE DYSCHROMATOPSIA
Certain medications can cause afferent visual problems, including abnormally tinted vision. Blue tinting, called cyanopsia, can occur after cataract extraction, but is also a rare dose-related side-effect of sildenafil [18] .
Xanthopsia, yellow vision tinting, can be caused by cataracts, and also by digitalis (digoxin) toxicity. Vincent Van Gogh, whose paintings are often tempered with a yellow hue, always painted his physician, Dr Paul-Ferdinand Gachet, holding a foxglove plant (Digitalis purpurea). This situation has led to the theory that Van Gogh was being over-treated with the herb, and thus suffering from digitalis poisoning.
In addition to dyschromatopsia, Digitalis can also cause photopsias [19] and decreased visual acuity. These effects do not necessarily indicate drug toxicity, as they can occur at normal serum levels [20] . Symptoms can resolve after drug discontinuation.
MEDICATIONS THAT MAY WORSEN DIPLOPIA OR PTOSIS IN NEUROMUSCULAR JUNCTION DISORDERS
Most patients with a disorder of the neuromuscular junction such as myasthenia gravis will eventually be prescribed a medication associated with worsening of their disease. Some of these medications are always contraindicated in myasthenia and others
KEY POINTS
Many prescription, over-the-counter, and recreational drugs can potentially cause ocular side-effects, some of which particularly induce, worsen, or mimic neuroophthalmological disorders.
Abnormal pupil responses or anisocoria should prompt a thorough review of medications, as well as all topically applied substances that may have contacted the area around the eye.
Accomodation problems are a common cause of blurry vision for which no organic cause is otherwise found. Many medications have cholinergic properties that may exacerbate this problem.
Some medications are purported to cause side-effects based on rare case reports or nonrandomized trials. Such associations should be recognized as possible, but confirmatory studies should be encouraged so that the true incidence of associations is known. Retina Photoreceptor dysfunction Vigabatrin Based on a prospective, ongoing cohort study, the reported incidence of visual field constriction associated with vigabatrin may actually be a phenomenon seen with epilepsy and other AEDs, and not restricted only to vigabatrin [11] Medication side-effects primarily causing neuro-ophthalmologic manifestations are not included in this table, and are discussed in detail below. This table is not inclusive, but includes a representation of the spectrum of diseases encountered in practice. AAO, American Academy of Ophthalmology; AED, antiepileptic drug; HAART, highly active antiretroviral therapy. are to be given only in extreme circumstances. However, some medications have caused worsening only in very rare cases, and can still be used with caution.
There are three types of potential medication interactions in patients with myasthenia. One group of medications may actually precipitate an iatrogenic myasthenia-like syndrome. These are listed in Table 4 
MEDICATIONS THAT MAY INDUCE PSEUDOTUMOR CEREBRI
Pseudotumor cerebri can be precipitated by certain medications. In these cases, it can be called One study used pupillometry to evaluate the effects of tramadol on pupil size. While 70% of subjects developed pupillary constriction, 30% had mydriasis [17] .
Neuroleptics Haloperidol, quetiapine
The combination of constricted pupils and confusion in a patient taking antipsychotics suggests neuroleptic overdose.
Serotonin receptor antagonist and reuptake inhibitors Trazodone Although trazodone also has some anticholinergic activity, and can cause side effects such as headaches, orthostatic dizziness, and dry mouth, its alpha-adrenergic blockade properties probably result in the pupil miosis.
Noradrenergic serotonergic antidepressants
Mirtazapine Pupil constriction has been reported as a feature of mirtazapine overdose.
Cholinergics Pyridostigmine Anticholinesterase properties result in contraction of the pupillary sphincter as well as impaired accommodation.
LSD, lysergic acid diethylamide; MAOs, monoamine oxidase inhibitors; MDMA, 3,4-methylenedioxy-N-methylamphetamine; SNRIs, serotonin and norepinephrine reuptake inhibitors; SSRIs, selective serotonin reuptake inhibitors. b-Blockers Labetolol, propranolol, atenolol, others. The common use of these medications results in questions of their safety in the patients with myasthenia. Although increased fatigue is common, true weakness is unlikely [27] .
Calcium channel blockers Amlodipine, nifedipine, nicardipine, others
Rare, but severe cases of both cardiogenic and respiratory decompensation have occurred in patients with myasthenia who received even one dose of calcium channel blocker.
HMG-CoA reductase inhibitors
Atorvastatin, pravastatin, rosuvastatin, others
Another ubiquitous medication, statins can be used in patients with myasthenia gravis when indicated [28] . Because statins can either potentially worsen myasthenia gravis or cause a statin myopathy, it is necessary to perform more extensive evaluation for a patient with myasthenia on statins who weakens. Antiepileptics Phenytoin, gabapentin, carbamazepine, barbiturates, ethosuximide
There are case reports of both phenytoin and gabapentin causing a worsening of myasthenia, but in general the overall risk of worsening in myasthenia gravis due to AEDs is relatively small. Phenytoin should probably be avoided in myasthenia gravis.
Ophthalmologic drops b-Blockers (e.g., timolol, betaxolol), ecothiophate, acetazolamide, proparacaine/tropicamide, Mostly case reports. These drops are not contraindicated, but an increase in symptoms in a myasthenic should prompt questioning of use.
Magnesium Parenteral or oral formulations
Relatively high doses of magnesium are given for preeclampsia, and myasthenia gravis may worsen or first manifest in this situation.
Psychiatric medications Lithium, tricyclics, phenothiazines (e.g., chlorpromazine).
The myasthenic effect may occur with nontoxic levels of medication and improve with lowering of the doses.
AED, antiepileptic drug; HMG-CoA, 3-hydroxy-3-methyl-glutaryl-CoA, reductase inhibitors.
represent PRES (see above). We found only one case report of phenytoin-related pseudotumor. The same is true for other medications (e.g., indomethacin, danazol), which appear in lists due to single cases reported many years ago. Tamoxifen is one such example, but a Medline search for 'Tamoxifen' and 'pseudotumor cerebri' or 'idiopathic intracranial hypertension' yielded no results. These examples highlight the need for continued re-examination and evaluation of the evidence.
MEDICATIONS THAT MAY CAUSE A DISTURBANCE IN EYE MOVEMENTS
Medication side-effects may manifest as efferent visual problems [46] . Often, these ocular side-effects are not isolated, rather part of widespread neurologic dysfunction suggesting medication toxicity. At times, the cause-effect relationship is fairly obvious, such as onabotulinum causing increased ptosis, after extraocular muscle (EOM) injections [47] . Other effects may be subtle, and patients have difficulty describing the problem. Eye movement recordings measuring velocity and gain may be helpful. Oculogyric crisis is a dystonic syndrome causing involuntary sustained deviation (usually upwards) of the eyes, mutism, mydriasis, neck dystonia, and agitation. The reaction may mimic encephalitis or seizure. When caused by medication, it is due to an extrapyramidal reaction Human growth hormone Also known as somatotropin HGH-associated IIH may occur in the absence of headache, obesity, or other common associations of the idiopathic variety, making close surveillance of patients on HGH necessary [44] HGH, human growth hormone; IIH, idiopathic intracranial hypertension.
from postsynaptic receptor blockade. Opsoclonus describes the rapid disorganized fast eye movements that can occur due to encephalitis or as a paraneoplastic reaction, and has no intersaccadic latency interval. Presence of either of these ocular motor disorders requires an evaluation of possible medication-related causes.
MEDICATIONS THAT MAY CAUSE ACCOMMODATION DEFECTS
Although not a neuro-ophthalmologic disorder per se, we have had frequent neuro-ophthalmology consultations for unexplained visual disturbance in which the diagnosis was medication-induced accommodation defect. For this reason, we are including a short discussion of this problem. Medications with anticholinergic effects are given for a wide variety of conditions, including glaucoma, Parkinson's disease, bladder incontinence, and chronic obstructive pulmonary disease. These agents exert their antagonist effects through a competitive blockade of receptors to the neurotransmitter acetylcholine. Cholinergic receptors are categorized as muscarinic or nicotinic based on their response to naturally occurring parasympathomimetic products. Muscarinic receptors (subtypes 1-5) are located in the bladder, gastrointestinal tract, eye, heart, brain, and salivary glands [55] . Binding of these receptors opposes the endogenous parasympathetic effects of acetylcholine in the central and peripheral nervous system, allowing for their pharmacologic effect.
The presence of muscarinic receptors on the ocular surface implicates cholinergic regulation in the pathogenesis or treatment for a number of ocular conditions [56] . We have already listed anticholinergics as exacerbating narrow angle glaucoma and discussed anticholinergics and pupil constriction. In addition to these effects is the potential disturbance of accommodation [57] . Just as muscarinic receptors located on the sphincter pupillae muscle are stimulated by the parasympathetic nervous system to contract smooth muscle and decrease the amount of light entering the eye, parasympathetic stimulation of muscarinic receptors on the ciliary muscle causes contraction of the smooth muscle, allowing for the lens to become more spherical and refractory to light. This accommodation allows the eye to view objects at varying distances. Paralysis of the ciliary muscle, referred to as cycloplegia, and subsequent loss of accommodation, are the ocular side-effects caused by muscarinic antagonists. Oculogyric crisis Carbamazepine, phenothiazines, lithium, lamotrigine [52] , metoclopramide [53] , cefixime [54] .
First generation neuroleptics are more likely to induce a crisis compared with second or third generation. Intravenous benztropine is a proposed treatment for an attack AEDs, antiepileptic drugs. Adverse ophthalmologic effects can be induced by a number of different classes of anticholinergic medications due to the ubiquitous distribution of muscarinic receptors in the body. Atropine, the prototype anticholinergic medication, is used to reduce motility in the gastrointestinal tract and to reduce respiratory secretions as pretreatment in anesthesia. In addition to classic antimuscarinic agents, other classes of drugs such as antihistamines, cimetidine, theophylline, and digoxin may have anticholinergic effects. Table 9 lists medications that can precipitate visual disturbance due to loss of accommodation.
MEDICATIONS THAT MAY CAUSE OPTIC NEUROPATHY
The optic nerve is a potential site for functional disruption due to drug side-effects [58] . An outline of these medications is listed in Table 10 
CONCLUSION
Medication use is based on a risk-benefit profile. Because new medications are constantly being developed within classes, and novel medication classes are themselves being created, the physician should remain updated on potential adverse reactions and side-effects. A critical evaluation of the strength of evidence linking a medication to its purported adverse reaction helps establish the most appropriate risk-benefit profile for each individual. 
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